Evidence map›Paper›PMID 36595144›Full record

ArticleInternational journal of hematology2023

Decision analysis of allogeneic bone marrow transplantation versus immunosuppressive therapy for young adult patients with aplastic anemia.

Yoshinobu Kanda, Kensuke Usuki, Mitsuhiro Inagaki, Akiko Ohta, Yoji Ogasawara, Naoshi Obara, Shinichi Kako, Mineo Kurokawa, Naoki Shimada, Takahiro Suzuki and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 1 country.

Yoshinobu KandaDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. ycanda-tky@umin.ac.jp.ORCID http://orcid.org/0000-0002-4866-9307
Kensuke UsukiNTT Medical Center Tokyo, Tokyo, Japan.
Mitsuhiro InagakiHiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Akiko OhtaSaitama Medical University, Saitama, Japan.
Yoji OgasawaraThe Jikei University School of Medicine, Tokyo, Japan.
Naoshi ObaraUniversity of Tsukuba, Tsukuba, Ibaraki, Japan.
Shinichi KakoJichi Medical University Saitama Medical Center, Saitama, Japan.
Mineo KurokawaThe University of Tokyo, Tokyo, Japan.
Naoki ShimadaInternational University of Health and Welfare, Otawara, Tochigi, Japan.
Takahiro SuzukiKitasato University, Kanagawa, Japan.
Asahito HamaJapanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.
Hiroki YamaguchiNippon Medical School, Tokyo, Japan.
Shinji NakaoKanazawa University Hospital, Kanazawa, Japan.
Hirohito YamazakiKanazawa University Hospital, Kanazawa, Japan.
Jichi Medical University · JPKanazawa University Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPInternational University of Health and Welfare · JPJikei University School of Medicine · JPKitasato University Hospital · JPNippon Medical School · JPNTT Medical Center · JPSaitama Medical University · JPThe University of Tokyo · JPUniversity of Tsukuba · JP

Funding

Ministry of Health, Labor and Welfare of Japan 20FC1018
6 · The paper itself

Abstract

backgroundAllogeneic bone marrow transplantation (BMT) from an HLA-matched sibling donor is recommended as an initial treatment for young patients. However, immunosuppressive therapy (IST) with cyclosporine and anti-thymocyte globulin may be a viable option even when an HLA-identical sibling donor is available.

methodsWe constructed a Markov model to simulate the 10-year clinical course of patients aged 21-40 years with newly diagnosed severe aplastic anemia. Immediate BMT and IST were compared as an initial treatment assuming the availability of an HLA-identical sibling donor. Transition probabilities after treatment were determined based on a registry data analysis for BMT and a long-term prospective study for IST.

resultsQuality-adjusted life years (QALYs) after treatment selection were 6.77 for BMT and 6.74 for IST. One-way sensitivity analysis revealed that the utility for being alive without GVHD after BMT, that for being alive with partial response after IST, and the response rate after initial IST strongly affected the results.

conclusionsBMT and IST produced similar QALY for young patients with severe aplastic anemia. An estimation of the response rate to the initial IST may enable an individualized comparison between BMT and IST.

Indexed as

Anemia, AplasticGraft vs Host DiseaseHematopoietic Stem Cell TransplantationBone Marrow TransplantationDecision Support TechniquesHumansImmunosuppression TherapyImmunosuppressive AgentsProspective StudiesYoung AdultImmunosuppressive AgentsBone marrow transplantationDecision analysisImmunosuppressive therapySevere aplastic anemia

Identifiers

PMID36595144
OpenAlexW4313454755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.